xProf Sir David Philip

[vc_row][vc_column][vc_single_image image=”427″ img_size=”1500X436″][/vc_column][/vc_row][vc_row][vc_column width=”1/3″][vc_column_text css=”.vc_custom_1563718558811{margin-left: 50px !important;}”]     [/vc_column_text][/vc_column][vc_column width=”1/2″][vc_column_text]

Prof Sir David Philip Lane FRS, FRSE, FRCPath., FRCS (Edinburgh), FmedSci., FUCL


Professor Sir David Lane is one of the scientists credited with the landmark discovery of cancer gene p53 in 1979. p53, called the “Guardian of the genome” is considered the most significant of all the genes altered in cancer cells because mutations of the gene are known to cause almost 50 percent of all human cancers. Professor Lane is currently the Chief Scientist of A*STAR, where his main role is to advise and engage in scientific development across the Biomedical Research Council (BMRC) and the Scientific Engineering Research Council (SERC) at the strategic level. He is the Director of the p53 Laboratory, which primarily focuses on research on protein interactions and how to develop drugs to inhibit such interactions using p53 as a model system. He was previously the Chairman of A*STAR’s Institute of Molecular and Cell Biology (IMCB) scientific advisory board from 2002 to 2003 and Executive Director, IMCB from 2004 to 2007, where he added on a translational focus to IMCB’s core strengths in basic R&D, recruited many outstanding scientists and personally led efforts to foster greater collaboration, both within and outside of IMCB. He was also the founding CEO of A*STAR’s Experimental Therapeutics Centre (ETC), which was set up in 2006. Professor Lane put in place a robust team of more than 60 scientists and built up top-of-the-line technological platforms essential for the drug discovery business. More recently Professor Lane helped establish Chugai Pharmabody Research (CPR) in Singapore. CPR employs over 100 staff at the Biopolis and is a wholly owned subsidiary of Chugai Pharmaceuticals, developing advanced antibody products. He was previously the Director of the Cancer Research UK Cell Transformation Research Group and Professor of Oncology at the University of Dundee in Scotland. He also held the position of Chief Scientist with Cancer Research UK and Scientific Director of the Ludwig Institute. For his efforts in cancer research, Professor Lane was knighted in 2000 and has won many awards such as the Paul Ehrlich Prize in 1998, the Buchanan Medal in 2004, the Medal of Honor from the International Agency for Research on Cancer in 2005 and the Royal Medal from the Royal Society of Edinburgh in 2008. He is a member of the European Molecular Biology Organisation (EMBO) and a Fellow of UK’s premier scientific academy, the Royal Society, the Royal Society of Edinburgh and a founder member of the Academy of Medical Science. For his important role in the strategic development of Singapore’s biomedical sciences and distinguished contributions to cancer therapeutics and research, Professor Lane was awarded the 2017 President’s Science and Technology Medal. Professor Lane has published more than 350 research articles in international peer reviewed journals, many of which have been very highly citied. He also co-authored a successful practical guide to the use of immunochemical methods called “Antibodies” with Ed Harlow, which has sold more than 50,000 copies.[/vc_column_text][/vc_column][/vc_row]